Impact of Medicare Drug Price Negotiations

This chapter examines the Biden administration's initiation of price negotiations for Medicare's top ten prescription drugs, projecting substantial savings ranging from 38% to 80%. It highlights the implications for pharmaceutical companies, including potential shifts in R&D investments and the likelihood of increased mergers and acquisitions due to new pricing policies. Additionally, the chapter provides insights into current market dynamics, including challenges in the auto sales sector and related economic concerns.